Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
IMTX — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

4.5

Margin Of Safety %

Put/Call OI Ratio

0.39

EPS Next Q Diff

0.01

EPS Last/This Y

-0.05

EPS This/Next Y

Price

9.63

Target Price

17.65

Analyst Recom

1

Performance Q

-13.38

Upside

-365.4%

Beta

1.33

Ticker: IMTX




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13IMTX9.233.8815.501683
2026-07-14IMTX9.343.970.671714
2026-07-15IMTX9.463.973.331716
2026-07-16IMTX9.44.004.001726
2026-07-17IMTX9.614.141.301779
2026-07-20IMTX9.210.390.00318
2026-07-21IMTX9.390.330.00356
2026-07-22IMTX9.180.330.00356
2026-07-23IMTX9.280.330.00356
2026-07-24IMTX9.090.330.00356
2026-07-27IMTX8.630.330.00356
2026-07-28IMTX8.740.330.00356
2026-07-29IMTX9.010.33999.99357
2026-07-30IMTX9.20.340.00358
2026-07-31IMTX8.660.33999.99359
2026-08-03IMTX9.020.34999.99360
2026-08-04IMTX9.350.34999.99360
2026-08-05IMTX9.780.34999.99360
2026-08-07IMTX9.640.390.00373
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13IMTX9.2328.7- -1.94
2026-07-14IMTX9.3528.7- -1.94
2026-07-15IMTX9.4628.7- -1.94
2026-07-16IMTX9.4128.7- -1.94
2026-07-17IMTX9.6328.7- -1.94
2026-07-20IMTX9.2428.7- -1.94
2026-07-21IMTX9.3828.7- -1.94
2026-07-22IMTX9.1728.7- -1.94
2026-07-23IMTX9.2928.7- -1.94
2026-07-24IMTX9.0928.7- -1.94
2026-07-27IMTX8.6228.7- -1.94
2026-07-28IMTX8.7328.7- -1.94
2026-07-29IMTX9.0028.7- -1.94
2026-07-30IMTX9.2128.7- -1.94
2026-07-31IMTX8.6728.7- -1.94
2026-08-03IMTX9.0228.7- -1.94
2026-08-04IMTX9.0228.7- -1.94
2026-08-05IMTX9.7828.7- -1.94
2026-08-06IMTX9.4228.7- -1.94
2026-08-07IMTX9.6329.8- -1.90
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13IMTX0.005.334.82
2026-07-14IMTX0.005.334.82
2026-07-15IMTX0.005.334.82
2026-07-16IMTX0.005.334.82
2026-07-17IMTX0.005.334.82
2026-07-20IMTX0.005.224.82
2026-07-21IMTX0.005.224.82
2026-07-22IMTX0.005.224.82
2026-07-23IMTX0.005.224.82
2026-07-24IMTX0.005.224.82
2026-07-27IMTX0.005.184.50
2026-07-28IMTX0.005.184.50
2026-07-29IMTX0.005.184.50
2026-07-30IMTX0.005.184.50
2026-07-31IMTX0.005.184.50
2026-08-03IMTX0.00-0.814.50
2026-08-04IMTX0.00-0.814.50
2026-08-05IMTX0.00-0.814.50
2026-08-06IMTX0.00-0.814.50
2026-08-07IMTX0.00-0.814.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.5

Avg. EPS Est. Current Quarter

-0.48

Avg. EPS Est. Next Quarter

-0.49

Insider Transactions

Institutional Transactions

-0.81

Beta

1.33

Average Sales Estimate Current Quarter

12

Average Sales Estimate Next Quarter

11

Fair Value

Quality Score

29

Growth Score

32

Sentiment Score

91

Actual DrawDown %

40.9

Max Drawdown 5-Year %

-77.4

Target Price

17.65

P/E

Forward P/E

PEG

P/S

29.86

P/B

2.51

P/Free Cash Flow

EPS

-1.97

Average EPS Est. Cur. Y​

-1.9

EPS Next Y. (Est.)

-1.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-572.25

Relative Volume

0.61

Return on Equity vs Sector %

-74.4

Return on Equity vs Industry %

-58.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

IMTX Healthcare
$9.65
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
2/20
Pullback
11/25
Volume
9/15
Valuation
10/20
TP/AR
2/10
Options
7/10
RSI
53.4
Range 1M
51.7%
Sup Dist
4.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
15 /100
WEAK
Momentum
2/25
Growth
4/30
Estimates
0/20
Inst/Vol
1/15
Options
8/10
EPS Yr
-4.8%
EPS NY
-0.1%
52W%
61.5%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +82.9% upside
Quality
2/30
Valuation
14/30
Growth
0/25
Stability
7/10
LT Trend
0/5
Upside
+82.9%
Quality
29
IMTX — P/E HistoricalBiotechnology
Immatics N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 678
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX

Latest News

Caricamento notizie per IMTX
stock quote shares IMTX – Immatics N.V Stock Price stock today
news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch IMTX – Immatics N.V yahoo finance google finance
stock history IMTX – Immatics N.V invest stock market
stock prices IMTX premarket after hours
ticker IMTX fair value insiders trading